European Information Network - Ethics in Medicine and Biotechnology
A project of the European Commission,Quality of Life and Management of Living Resources Programme
|
|
European Information Network - Ethics in Medicine and BiotechnologyA project of the European Commission,Quality of Life and Management of Living Resources Programme |
| Eureth.net Home | News | Events | Literature | Partners | Topics | Links | ENDEBIT | EUROETHICS | Thesaurus |
| DRZEs Eurethnet-Home | Contact us |
If you require further information, please contact the organizers directly.
| Back to calendar |
|
| Date: | 26.01.2010 to 27.01.2010 |
| Location: | Résidence Palace – International Press Centre
Rue de la Loi 155
1040 Brussels
Belgium Brüssel Belgien |
| Keywords: | Health care system/Health policy - Medical ethics |
| Details: | For the past 50 years the development of new medicines has been highly successful. As a result, many diseases have been well treated – sometimes cured or at least their symptoms relieved. Success could be measured by the number of patients thus treated. However, such success had to be leavened by the frequency of side effects and it had to be recognised that potential success for an individual patient could be nullified by the unacceptability of such side effects. So attempts were made both to increase the efficacy of new medicines and to improve their tolerability; and, in parallel, it was realised that efficacy and tolerability of any given medicine varied between individual patients. The traditional tools for finding the right dose for most patients were randomized controlled clinical trials and post-marketing surveillance studies; but, recently, the recognition that the individual genetic profiles of patients could be identified in terms of their susceptibility to treatment with medicines as well as their susceptibility to the side effects of such medicines has enabled a paradigm shift towards the success of a new medicine. Knowledge about the individual genome has clearly opened up huge scientific opportunities, but accompanied by a significant need to identify, discuss and attempt to solve aspects of personalized medicine related to society as a whole. This conference will tackle the complex issues involved, including the ethics of providing confidential information arising from knowledge of the individual genome, associated economic factors, access to tailor-made treatment and how this should be prioritised. By means of a series of presentations by those experienced in handling these issues, and six interactive workshops, the EFGCP Annual Conference 2010 will aim to identify the challenges of personalized medicine in the context of society as a whole yet to be met. The various roles of all the stakeholders, from the bench-based scientist to the patient, will all be discussed in the interests of identifying the best possible treatments for the society of the future. |
| Organizer: | The European Forum for Good Clinical Practice (EFGCP) |
| Contact: | Address: EFGCP Secretariat Square de Meeûs Rue de l'Industrie 4 1000 Brussels Belgium Tel: +32 - 2 - 7 32 87 83 Fax: +32 - 2 - 5 03 31 08 Email: conferences@efgcp.be |
| Webpage: | http://www.efgcp.be/Conference_details.asp?id=235&L1=10&L2=1&TimeRef=1 |
| Eureth.net Home | News | Events | Literature | Partners | Topics | Links | ENDEBIT | EUROETHICS | Thesaurus |
| EURETHNET site at © DRZE: last update 21.05.2008 General information | Administration: webmaster@drze.de |